Scientists have received approval from the US Food and Drug Administration (FDA) to use 'Tumour Paint' a product derived from scorpion venom for study in human trials in the US in an effort to treat people suffering from brain cancer. During the phase one trial 'Tumour Paint' will be used on an estimated 21 people with a glioma or tumour in the brain or spine ABCNews.com reported. The product was developed by US-based Blaze Bioscience a company dedicated to developing products that assist physicians in their quest to improve the lives of cancer patients. 'Tumour Paint' is designed to 'provide